Orchard Therapeutics Gestione
Gestione criteri di controllo 4/4
Orchard Therapeutics Il CEO è Bobby Gaspar, nominato in Mar2020, e ha un mandato di 3.83 anni. la retribuzione annua totale è $ 1.45M, composta da 39.6% di stipendio e 60.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.16% delle azioni della società, per un valore di $ 611.47K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.7 anni e 5.6 anni.
Informazioni chiave
Bobby Gaspar
Amministratore delegato
US$1.4m
Compenso totale
| Percentuale dello stipendio del CEO | 39.6% |
| Mandato del CEO | 3.8yrs |
| Proprietà del CEO | 0.2% |
| Durata media del management | 2.7yrs |
| Durata media del Consiglio di amministrazione | 5.6yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR
Jan 19Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price
May 09
Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?
Mar 10Orchard Therapeutics: Gene Therapy For Rare Child Disease
Aug 19Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M
Aug 04Orchard Therapeutics: Shadow Of Former Glory
Jan 20Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles
Aug 16Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?
Jun 14What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?
Feb 03Orchard Therapeutics appoints Braden Parker as chief commercial officer
Jan 29Orchard Therapeutics' OTL-200 wins FDA's RMAT status
Jan 14Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022
Jan 12Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?
Jan 08Orchard Therapeutics' MLD gene therapy wins European nod
Dec 21Our View On Orchard Therapeutics
Dec 17Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year
Dec 11Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study
Dec 08Orchard Therapeutics (ORTX) Investor Presentation - Slideshow
Nov 22Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$73m |
| Jun 30 2023 | n/a | n/a | -US$85m |
| Mar 31 2023 | n/a | n/a | -US$124m |
| Dec 31 2022 | US$1m | US$573k | -US$151m |
| Sep 30 2022 | n/a | n/a | -US$179m |
| Jun 30 2022 | n/a | n/a | -US$168m |
| Mar 31 2022 | n/a | n/a | -US$154m |
| Dec 31 2021 | US$4m | US$605k | -US$145m |
| Sep 30 2021 | n/a | n/a | -US$142m |
| Jun 30 2021 | n/a | n/a | -US$126m |
| Mar 31 2021 | n/a | n/a | -US$137m |
| Dec 31 2020 | US$4m | US$543k | -US$152m |
| Sep 30 2020 | n/a | n/a | -US$164m |
| Jun 30 2020 | n/a | n/a | -US$180m |
| Mar 31 2020 | n/a | n/a | -US$183m |
| Dec 31 2019 | US$921k | US$344k | -US$163m |
| Sep 30 2019 | n/a | n/a | -US$143m |
| Jun 30 2019 | n/a | n/a | -US$140m |
| Mar 31 2019 | n/a | n/a | -US$246m |
| Dec 31 2018 | US$2m | US$338k | -US$230m |
Compensazione vs Mercato: La retribuzione totale di Bobby ($USD 1.45M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 2.18M ).
Compensazione vs guadagni: La retribuzione di Bobby è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Bobby Gaspar (60 yo)
3.8yrs
Mandato
US$1,447,526
Compensazione
Dr. Hubert Baburaj Gaspar, M.D. Ph.D. also known as Bobby, has been Chief Executive Officer at Orchard Therapeutics plc (Formerly known as Orchard Therapeutics Limited) since March 18, 2020. He serves as a...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, Member of Scientific Advisory Board & Executive Director | 3.8yrs | US$1.45m | 0.16% $ 611.5k | |
| President & COO | 4yrs | US$1.21m | 0.040% $ 153.8k | |
| Chief Technical Officer | 2.3yrs | Nessun dato | Nessun dato | |
| Chief Scientific Officer | 2yrs | Nessun dato | Nessun dato | |
| Head of Investor Relations | no data | Nessun dato | Nessun dato | |
| Director of Corporate Communications | no data | Nessun dato | Nessun dato | |
| Chief Human Resource Officer | no data | Nessun dato | Nessun dato | |
| Senior VP & GM of EMEA Commercial Operations | 5.2yrs | Nessun dato | Nessun dato | |
| Chief Commercial Officer | 3yrs | Nessun dato | Nessun dato | |
| Chief Medical Officer | 2.3yrs | Nessun dato | Nessun dato | |
| Company Secretary | 1.9yrs | Nessun dato | Nessun dato |
2.7yrs
Durata media
Gestione esperta: Il team dirigenziale di ORTX è considerato esperto (durata media dell'incarico 2.7 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, Member of Scientific Advisory Board & Executive Director | 7.9yrs | US$1.45m | 0.16% $ 611.5k | |
| Independent Chairman | 5.7yrs | US$107.72k | 0.019% $ 74.1k | |
| Independent Non-Executive Director | 5.6yrs | US$71.72k | 0.016% $ 62.1k | |
| Independent Non-Executive Director | 5.5yrs | US$90.72k | 0.0054% $ 20.5k | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato |
5.6yrs
Durata media
67yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ORTX sono considerati esperti (durata media dell'incarico 5.6 anni).